Trial Profile
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients with Metastatic Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Panitumumab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 16 Apr 2019 Status changed from active, no longer recruiting to completed.
- 10 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.
- 10 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.